» Articles » PMID: 35924161

Impairment of RAD17 Functions by MiR-506-3p As a Novel Synthetic Lethal Approach Targeting DNA Repair Pathways in Ovarian Cancer

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Aug 4
PMID 35924161
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial ovarian cancer (EOC) remains the most lethal gynecological cancer and development of chemo-resistance is a major factor in disease relapse. Homologous recombination (HR) is a critical pathway for DNA double strand break repair and its deficiency is associated to a better response to DNA damage-inducing agents. Strategies to inhibit HR-mediated DNA repair is a clinical need to improve patients' outcome. MicroRNA (miRNAs) affect most of cellular processes including response to cancer treatment. We previously showed that miR-506-3p targets , an essential HR component. In this study we demonstrated that: i) another HR component, , is also a direct target of miR-506-3p and that it is involved in mediating miR-506-3p phenotypic effects; ii) the impairment of miR-506-3p binding to 3' UTR reverted the miR-506-3p induced platinum sensitization; iii) miR-506-3p/RAD17 axis reduces the ability of EOC cell to sense DNA damage, abrogates the G2/M cell cycle checkpoint thus delaying the G2/M cell cycle arrest likely allowing the entry into mitosis of heavily DNA-damaged cells with a consequent mitotic catastrophe; iv) RAD17 expression, regulated by miR-506-3p, is synthetically lethal with inhibitors of cell cycle checkpoint kinases Chk1 and Wee1 in platinum resistant cell line. Overall miR-506-3p expression may recapitulate a BRCAness phenotype sensitizing EOC cells to chemotherapy and helping in selecting patients susceptible to DNA damaging drugs in combination with new small molecules targeting DNA-damage repair pathway.

Citing Articles

Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial.

Pellegrino B, Capoluongo E, Bagnoli M, Arenare L, Califano D, Scambia G ESMO Open. 2025; 10(1):104091.

PMID: 39754985 PMC: 11758122. DOI: 10.1016/j.esmoop.2024.104091.


Identification of RAD17 as a candidate cancer predisposition gene in families with histories of pancreatic and breast cancers.

Joris S, Giron P, Olsen C, Seneca S, Gheldof A, Staessens S BMC Cancer. 2024; 24(1):723.

PMID: 38872153 PMC: 11170902. DOI: 10.1186/s12885-024-12442-z.


Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors.

Alam S, Giri P Cancer Drug Resist. 2024; 7:6.

PMID: 38434767 PMC: 10905178. DOI: 10.20517/cdr.2023.152.

References
1.
Coleman R, Fleming G, Brady M, Swisher E, Steffensen K, Friedlander M . Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019; 381(25):2403-2415. PMC: 6941439. DOI: 10.1056/NEJMoa1909707. View

2.
Barnes B, Nelson L, Tighe A, Burghel G, Lin I, Desai S . Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes. Genome Med. 2021; 13(1):140. PMC: 8408985. DOI: 10.1186/s13073-021-00952-5. View

3.
Jackson S, Bartek J . The DNA-damage response in human biology and disease. Nature. 2009; 461(7267):1071-8. PMC: 2906700. DOI: 10.1038/nature08467. View

4.
Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D . MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol. 2014; 233(3):308-18. PMC: 4144705. DOI: 10.1002/path.4348. View

5.
Gyorffy B, Lanczky A, Szallasi Z . Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012; 19(2):197-208. DOI: 10.1530/ERC-11-0329. View